Physician profile
Dev G Mehta
NPI 1942688288
$2,841.84
in general payments reported to CMS, 2019-2025
10 companies · $458 in 2025
The $458 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2021: $281 · 2022: $295 · 2023: $466 · 2024: $696 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.72 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,735.26 | 2021-2025 | |
| Lilly USA, LLC | $293.23 | 2023-2025 | Emgality, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.77 | 2019 | |
| Genentech USA, INC. | $150.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.80 | 2019 | |
| Emd Serono, INC. | $105.84 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $21.29 | 2025 | Wainua |
| Acadia Pharmaceuticals INC | $15.65 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dev Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.